\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ information\\ provided\ \(0\)\
\-\ skin\\:\\ laser\\ tx\\ for\\ cosmesis\ \(0\)\
\-\ glaucoma\\:\\ close\\ follow\\-up\\ with\\ ophthalmology\\ with\\ goal\\ to\\ preserve\\ vision\\ and\\ control\\ iop\\ via\\ medications\\ and\\/or\\ surgery\\.\ \(0\)\
\-\ follow\\ up\\ imaging\\ to\\ track\\ disease\\ progression\\ in\\ presence\\ of\\ new\\ onset\\ of\\ sx\\,\\ seizures\\,\\ etc\\.\\.\ \(0\)\
\-\ focal\\ cortical\\ hypoplasia\\ of\\ the\\ left\\ occipital\\ lobe\\ seen\\ with\\ decreased\\ t2\\ signal\\ of\\ deep\\ white\\ matter\\,\\ along\\ with\\ increased\\ enhancement\\ of\\ overlying\\ leptomeninges\\ in\\ comparison\\ with\\ right\\.\\ \\ increased\\ signal\\ intensity\\ and\\ size\\ of\\ choroidal\\ plexus\\ noted\\ in\\ occipital\\ horn\\ of\\ left\\ ventricle\\ in\\ comparison\\ with\\ right\\.\\ \\ increased\\ pial\\ enhancement\\ of\\ left\\ parietal\\ lobe\\ in\\ comparison\\ with\\ right\\.\ \(0\)\
\-\ left\\ globe\\ enlargement\\ in\\ comparison\\ with\\ right\\ globe\\ \\(measured\\ at\\ 2\\.5\\ cm\\ vs\\ 2\\.0\\ cm\\ ap\\)\\.\ \(0\)\
\-\ sturge\\-weber\\ syndrome\ \(0\)\
\-\ findings\\ consistent\\ with\\ known\\ sturge\\-weber\\ syndrome\ \(0\)\
\-\ may\\ consider\\:\\ wyburn\\-mason\\ syndrome\\,\\ other\\ phakomatoses\ \(0\)\
\-\ 11\\ mo\\ female\\ with\\ known\\ syndrome\\ and\\ a\\ recent\\ diagnosis\\ of\\ glaucoma\\.\\ \\ no\\ history\\ of\\ developmental\\ delays\\ or\\ seizure\\ activity\\.\\ \\ procedure\\:\\ baseline\\ mri\\ of\\ brain\\ with\\ gadolinium\\ for\\ evaluation\\ of\\ disease\\ progression\\ in\\ future\\.\ \(0\)\
\-\ sturge\\-weber\\ syndrome\\ \\(sws\\)\\ or\\ encephalotrigeminal\\ angiomatosis\\ is\\ a\\ non\\-heritable\\ congenital\\ neurocutaneous\\ disorder\\ associated\\ with\\ vascular\\ malformations\\ of\\ the\\ leptomeninges\\,\\ choroid\\ of\\ the\\ eye\\,\\ and\\ skin\\ of\\ the\\ face\\ with\\ a\\ trigeminal\\ distribution\\.\\ \\ findings\\ are\\ ipsilateral\\ in\\ the\\ overwhelming\\ majority\\ of\\ patients\\,\\ but\\ can\\ also\\ be\\ bilateral\\.1\\ \\ pathogenesis\\ is\\ theorized\\ to\\ be\\ associated\\ with\\ inappropriate\\ control\\ of\\ normal\\ vascular\\ maturation\\ and\\ a\\ resultant\\ persistence\\ of\\ the\\ primitive\\ vascular\\ plexus2\\.\\ \\ diagnosis\\ is\\ based\\ on\\ demonstration\\ of\\ port\\-wine\\ stain\\ in\\ a\\ trigeminal\\ distribution\\ \\(not\\ pathognomonic\\)\\ and\\ leptomeningeal\\ angiomas\\,\\ although\\ variants\\ also\\ occur\\ with\\ an\\ absence\\ of\\ one\\ of\\ these\\ findings\\ in\\ the\\ presence\\ of\\ ocular\\ angiomas\\.3\\ \\ \ \(0\)\
\-\ the\\ predominant\\ ocular\\ feature\\ is\\ glaucoma\\,\\ with\\ a\\ congenital\\ presentation\\ seen\\ in\\ 50\\%\\ of\\ patients\\.\\ \\ early\\ presentation\\ in\\ the\\ newborn\\ begins\\ as\\ bupthalmos\\,\\ or\\ enlargement\\ of\\ the\\ globe\\.\\ \\ other\\ ocular\\ findings\\ include\\ choroidal\\ angiomas\\,\\ heterochromia\\ of\\ the\\ iris\\,\\ or\\ visual\\ field\\ defects\\,\\ such\\ as\\ homonymous\\ hemianopsia\\,\\ secondary\\ to\\ occipital\\ cortex\\ atrophy4\\.\ \(0\)\
\-\ neurologic\\ features\\ are\\ progressive\\ and\\ include\\ seizures\\,\\ focal\\ deficits\\,\\ and\\ mental\\ retardation\\,\\ although\\ it\\ is\\ possible\\ to\\ be\\ spared\\ neurologic\\ abnormalities\\.\\ \\ typically\\ children\\ will\\ have\\ no\\ developmental\\ delay\\ for\\ several\\ months\\ after\\ birth\\,\\ but\\ may\\ begin\\ to\\ slow\\ in\\ their\\ cognitive\\ development\\ as\\ the\\ disease\\ progresses\\.\\ \\ mechanism\\ for\\ this\\ progression\\ is\\ suggested\\ to\\ be\\ secondary\\ to\\ hypoxic\\ ischemia\\ in\\ tissues\\ that\\ failed\\ to\\ vascularize\\ appropriately\\ adjacent\\ to\\ the\\ leptomeningeal\\ angiomas\\.4\\ \\ seizures\\ are\\ often\\ the\\ presenting\\ symptom\\.\\ \\ their\\ frequency\\,\\ age\\ at\\ onset\\,\\ and\\ response\\ to\\ treatment\\ affect\\ prognosis4\\.\ \(0\)\
\-\ mri\\ reveals\\ the\\ angioma\\ as\\ a\\ hyperintense\\ enhancement\\ of\\ the\\ leptomeninges\\ on\\ t2\\-weighted\\ images\\ frequently\\ occipital\\ or\\ posterior\\ temporoparietal\\,\\ with\\ atrophy\\ of\\ adjacent\\ lobe\\.\\ \\ choroidal\\ angiomas\\ enhance\\ on\\ fat\\ suppressed\\ t1\\ imaging\\.3\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ angiomas\\:\\ 0\\.2832228608542028\ \(0\)\
\-\ of\\:\\ 0\\.2328955955946675\ \(0\)\
\-\ leptomeninges\\:\\ 0\\.17660244971039912\ \(0\)\
\-\ glaucoma\\:\\ 0\\.16993371651252165\ \(0\)\
\-\ comparison\\:\\ 0\\.1679423233357205\ \(0\)\
\-\ choroidal\\:\\ 0\\.16053466496934599\ \(0\)\
\-\ in\\:\\ 0\\.1535105634820772\ \(0\)\
\-\ occipital\\:\\ 0\\.15086734605079125\ \(0\)\
\-\ with\\:\\ 0\\.1467255837473396\ \(0\)\
\-\ the\\:\\ 0\\.14072078969559307\ \(0\)\
\-\ globe\\:\\ 0\\.13779814703041535\ \(0\)\
\-\ ocular\\:\\ 0\\.13550112940105996\ \(0\)\
\-\ syndrome\\:\\ 0\\.13286294558967723\ \(0\)\
\-\ progression\\:\\ 0\\.12125238837908835\ \(0\)\
\-\ to\\:\\ 0\\.12121204818605076\ \(0\)\
\-\ seizures\\:\\ 0\\.10794450834773775\ \(0\)\
\-\ trigeminal\\:\\ 0\\.09765592227998052\ \(0\)\
\-\ leptomeningeal\\:\\ 0\\.0932101001480622\ \(0\)\
\-\ or\\:\\ 0\\.09200256989959461\ \(0\)\
\-\ and\\:\\ 0\\.09108066387188982\ \(0\)\
\-\ vascular\\:\\ 0\\.08729777517790048\ \(0\)\
\-\ findings\\:\\ 0\\.087015967515029\ \(0\)\
\-\ lobe\\:\\ 0\\.07641633379002828\ \(0\)\
\-\ developmental\\:\\ 0\\.07623220929190963\ \(0\)\
\-\ enhancement\\:\\ 0\\.07611064698623776\ \(0\)\
\-\ control\\:\\ 0\\.07532289160302603\ \(0\)\
\-\ distribution\\:\\ 0\\.07478059237344398\ \(0\)\
\-\ their\\:\\ 0\\.07316301861783847\ \(0\)\
\-\ is\\:\\ 0\\.0724254626861041\ \(0\)\
\-\ be\\:\\ 0\\.0715218450964649\ \(0\)\
\-\ increased\\:\\ 0\\.07150497484014151\ \(0\)\
\-\ as\\:\\ 0\\.07082991160555681\ \(0\)\
\-\ plexus2\\:\\ 0\\.07048944584593456\ \(0\)\
\-\ bupthalmos\\:\\ 0\\.07048944584593456\ \(0\)\
\-\ heterochromia\\:\\ 0\\.07048944584593456\ \(0\)\
\-\ atrophy4\\:\\ 0\\.07048944584593456\ \(0\)\
\-\ vascularize\\:\\ 0\\.07048944584593456\ \(0\)\
\-\ prognosis4\\:\\ 0\\.07048944584593456\ \(0\)\
\-\ neurologic\\:\\ 0\\.07044171836553934\ \(0\)\
\-\ enlargement\\:\\ 0\\.06758393922707541\ \(0\)\
\-\ cosmesis\\:\\ 0\\.067356428664876\ \(0\)\
\-\ sws\\:\\ 0\\.067356428664876\ \(0\)\
\-\ encephalotrigeminal\\:\\ 0\\.067356428664876\ \(0\)\
\-\ skin\\:\\ 0\\.06557900160542898\ \(0\)\
\-\ theorized\\:\\ 0\\.06513351759891683\ \(0\)\
\-\ presence\\:\\ 0\\.0633401322886903\ \(0\)\
\-\ congenital\\:\\ 0\\.0633401322886903\ \(0\)\
\-\ phakomatoses\\:\\ 0\\.062000500417858276\ \(0\)\
\-\ iris\\:\\ 0\\.062000500417858276\ \(0\)\
\-\ temporoparietal\\:\\ 0\\.062000500417858276\ \(0\)\
\-\ delays\\:\\ 0\\.06080938256649973\ \(0\)\
\-\ neurocutaneous\\:\\ 0\\.06080938256649973\ \(0\)\
\-\ overwhelming\\:\\ 0\\.06080938256649973\ \(0\)\
\-\ presentation\\:\\ 0\\.06068436834375957\ \(0\)\
\-\ left\\:\\ 0\\.06014312458798961\ \(0\)\
\-\ although\\:\\ 0\\.06001417368979019\ \(0\)\
\-\ iop\\:\\ 0\\.05977758935189912\ \(0\)\
\-\ maturation\\:\\ 0\\.05977758935189912\ \(0\)\
\-\ angiomatosis\\:\\ 0\\.05886748323679971\ \(0\)\
\-\ inappropriate\\:\\ 0\\.05886748323679971\ \(0\)\
\-\ right\\:\\ 0\\.05845399997379659\ \(0\)\
\-\ preserve\\:\\ 0\\.0580533655749833\ \(0\)\
\-\ pial\\:\\ 0\\.0580533655749833\ \(0\)\
\-\ homonymous\\:\\ 0\\.0580533655749833\ \(0\)\
\-\ adjacent\\:\\ 0\\.057142027452398665\ \(0\)\
\-\ known\\:\\ 0\\.05707409792657317\ \(0\)\
\-\ onset\\:\\ 0\\.05660677248742662\ \(0\)\
\-\ disease\\:\\ 0\\.05550644892970683\ \(0\)\
\-\ sx\\:\\ 0\\.05545345431948201\ \(0\)\
\-\ variants\\:\\ 0\\.05545345431948201\ \(0\)\
\-\ laser\\:\\ 0\\.05395321640286428\ \(0\)\
\-\ for\\:\\ 0\\.05343815302570225\ \(0\)\
\-\ focal\\:\\ 0\\.052730282384437416\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.05269743732796558\ \(0\)\
\-\ include\\:\\ 0\\.05245136855504863\ \(0\)\
\-\ spared\\:\\ 0\\.052320437138423444\ \(0\)\
\-\ secondary\\:\\ 0\\.052251637926859634\ \(0\)\
\-\ ophthalmology\\:\\ 0\\.051960978321048824\ \(0\)\
\-\ hemianopsia\\:\\ 0\\.051617500835371796\ \(0\)\
\-\ retardation\\:\\ 0\\.051617500835371796\ \(0\)\
\-\ progresses\\:\\ 0\\.051617500835371796\ \(0\)\
\-\ persistence\\:\\ 0\\.05128864392382283\ \(0\)\
\-\ begin\\:\\ 0\\.05097321355104975\ \(0\)\
\-\ cognitive\\:\\ 0\\.05097321355104975\ \(0\)\
\-\ t2\\:\\ 0\\.05071795285875149\ \(0\)\
\-\ hypoxic\\:\\ 0\\.05067015623315639\ \(0\)\
\-\ suppressed\\:\\ 0\\.05067015623315639\ \(0\)\
\-\ cm\\:\\ 0\\.05062836453688402\ \(0\)\
\-\ primitive\\:\\ 0\\.05037853780872343\ \(0\)\
\-\ feature\\:\\ 0\\.05037853780872343\ \(0\)\
\-\ are\\:\\ 0\\.050176168348426135\ \(0\)\
\-\ goal\\:\\ 0\\.05009752607246429\ \(0\)\
\-\ demonstration\\:\\ 0\\.05009752607246429\ \(0\)\
\-\ signal\\:\\ 0\\.04997251184972413\ \(0\)\
\-\ patients\\:\\ 0\\.04959195779094389\ \(0\)\
\-\ predominant\\:\\ 0\\.049564420146907005\ \(0\)\
\-\ track\\:\\ 0\\.04906573285786368\ \(0\)\
\-\ mo\\:\\ 0\\.04906573285786368\ \(0\)\
\-\ appropriately\\:\\ 0\\.04859728815584656\ \(0\)\
\-\ tx\\:\\ 0\\.04837330229554846\ \(0\)\
\-\ begins\\:\\ 0\\.04837330229554846\ \(0\)\
\-\ stain\\:\\ 0\\.04794391566045866\ \(0\)\
\-\ follow\\:\\ 0\\.047523151317024004\ \(0\)\
\-\ baseline\\:\\ 0\\.0466050500740311\ \(0\)\
\-\ associated\\:\\ 0\\.046464248022320284\ \(0\)\
\-\ imaging\\:\\ 0\\.04632838831441616\ \(0\)\
\-\ resultant\\:\\ 0\\.046261572588354075\ \(0\)\
\-\ angioma\\:\\ 0\\.046261572588354075\ \(0\)\
\-\ other\\:\\ 0\\.04578025982813845\ \(0\)\
\-\ diagnosis\\:\\ 0\\.04569888027071712\ \(0\)\
\-\ ipsilateral\\:\\ 0\\.04561728530403203\ \(0\)\
\-\ affect\\:\\ 0\\.04561728530403203\ \(0\)\
\-\ mri\\:\\ 0\\.04525090855012092\ \(0\)\
\-\ symptom\\:\\ 0\\.04488082629711528\ \(0\)\
\-\ malformations\\:\\ 0\\.04447044821065554\ \(0\)\
\-\ failed\\:\\ 0\\.04447044821065554\ \(0\)\
\-\ may\\:\\ 0\\.044362330174766894\ \(0\)\
\-\ future\\:\\ 0\\.044208491899889284\ \(0\)\
\-\ up\\:\\ 0\\.04360691193777598\ \(0\)\
\-\ but\\:\\ 0\\.04359274050877497\ \(0\)\
\-\ information\\:\\ 0\\.04359000420922284\ \(0\)\
\-\ hypoplasia\\:\\ 0\\.04347203289297254\ \(0\)\
\-\ horn\\:\\ 0\\.04347203289297254\ \(0\)\
\-\ measured\\:\\ 0\\.04347203289297254\ \(0\)\
\-\ newborn\\:\\ 0\\.04347203289297254\ \(0\)\
\-\ etc\\:\\ 0\\.043355835648850635\ \(0\)\
\-\ consider\\:\\ 0\\.043355835648850635\ \(0\)\
\-\ pathognomonic\\:\\ 0\\.043355835648850635\ \(0\)\
\-\ no\\:\\ 0\\.043000460224733514\ \(0\)\
\-\ slow\\:\\ 0\\.04248426812297346\ \(0\)\
\-\ frequency\\:\\ 0\\.04188959238064714\ \(0\)\
\-\ atrophy\\:\\ 0\\.0417011203267495\ \(0\)\
\-\ mechanism\\:\\ 0\\.04151713613191301\ \(0\)\
\-\ seen\\:\\ 0\\.04150261762595368\ \(0\)\
\-\ also\\:\\ 0\\.0414655429766423\ \(0\)\
\-\ field\\:\\ 0\\.04142676117042891\ \(0\)\
\-\ choroid\\:\\ 0\\.04133743102959698\ \(0\)\
\-\ suggested\\:\\ 0\\.04124912182701338\ \(0\)\
\-\ response\\:\\ 0\\.04065769886146476\ \(0\)\
\-\ delay\\:\\ 0\\.040417462793029456\ \(0\)\
\-\ majority\\:\\ 0\\.0400329570457128\ \(0\)\
\-\ on\\:\\ 0\\.03993644374182219\ \(0\)\
\-\ close\\:\\ 0\\.03988435686747217\ \(0\)\
\-\ plexus\\:\\ 0\\.03973856063414895\ \(0\)\
\-\ face\\:\\ 0\\.03973856063414895\ \(0\)\
\-\ enhance\\:\\ 0\\.03945497023238237\ \(0\)\
\-\ birth\\:\\ 0\\.039385669578428845\ \(0\)\
\-\ mental\\:\\ 0\\.03841448036956904\ \(0\)\
\-\ vision\\:\\ 0\\.03817486516579369\ \(0\)\
\-\ ischemia\\:\\ 0\\.03817486516579369\ \(0\)\
\-\ defects\\:\\ 0\\.03799990740183292\ \(0\)\
\-\ deficits\\:\\ 0\\.03788543166181112\ \(0\)\
\-\ visual\\:\\ 0\\.03760644933360601\ \(0\)\
\-\ overlying\\:\\ 0\\.037551841536563574\ \(0\)\
\-\ disorder\\:\\ 0\\.03728444561197088\ \(0\)\
\-\ medications\\:\\ 0\\.03697532554671171\ \(0\)\
\-\ gadolinium\\:\\ 0\\.03672684847376632\ \(0\)\
\-\ seizure\\:\\ 0\\.03667809770561037\ \(0\)\
\-\ development\\:\\ 0\\.03643885348251643\ \(0\)\
\-\ frequently\\:\\ 0\\.03629878370526451\ \(0\)\
\-\ provided\\:\\ 0\\.03616120788489529\ \(0\)\
\-\ children\\:\\ 0\\.03611588827626346\ \(0\)\
\-\ via\\:\\ 0\\.03602603876247745\ \(0\)\
\-\ cortex\\:\\ 0\\.03589319357999566\ \(0\)\
\-\ parietal\\:\\ 0\\.03559182503298026\ \(0\)\
\-\ features\\:\\ 0\\.03546618045778624\ \(0\)\
\-\ eye\\:\\ 0\\.03526120899310923\ \(0\)\
\-\ procedure\\:\\ 0\\.035140786226609516\ \(0\)\
\-\ absence\\:\\ 0\\.035140786226609516\ \(0\)\
\-\ hyperintense\\:\\ 0\\.03506153454601173\ \(0\)\
\-\ tissues\\:\\ 0\\.03475241448075255\ \(0\)\
\-\ presenting\\:\\ 0\\.03452842862045446\ \(0\)\
\-\ deep\\:\\ 0\\.034310753067670265\ \(0\)\
\-\ progressive\\:\\ 0\\.0337585917166201\ \(0\)\
\-\ vs\\:\\ 0\\.033626503523717294\ \(0\)\
\-\ matter\\:\\ 0\\.03356129662939401\ \(0\)\
\-\ reveals\\:\\ 0\\.03352889838016346\ \(0\)\
\-\ at\\:\\ 0\\.033297225335129445\ \(0\)\
\-\ 11\\:\\ 0\\.03299794811681052\ \(0\)\
\-\ ventricle\\:\\ 0\\.03244474602616401\ \(0\)\
\-\ occur\\:\\ 0\\.032416698913260066\ \(0\)\
\-\ activity\\:\\ 0\\.03236090826568009\ \(0\)\
\-\ based\\:\\ 0\\.03192851736495316\ \(0\)\
\-\ abnormalities\\:\\ 0\\.03192851736495316\ \(0\)\
\-\ early\\:\\ 0\\.03177241162893802\ \(0\)\
\-\ cortical\\:\\ 0\\.03164469019010528\ \(0\)\
\-\ ap\\:\\ 0\\.03164469019010528\ \(0\)\
\-\ intensity\\:\\ 0\\.03129790893278753\ \(0\)\
\-\ typically\\:\\ 0\\.030942855458246786\ \(0\)\
\-\ 50\\:\\ 0\\.030782586607994506\ \(0\)\
\-\ new\\:\\ 0\\.030493486342658725\ \(0\)\
\-\ possible\\:\\ 0\\.02986493093575195\ \(0\)\
\-\ size\\:\\ 0\\.029844834770662722\ \(0\)\
\-\ recent\\:\\ 0\\.029844834770662722\ \(0\)\
\-\ along\\:\\ 0\\.02953020724179096\ \(0\)\
\-\ white\\:\\ 0\\.029081055860961744\ \(0\)\
\-\ several\\:\\ 0\\.02891913435940997\ \(0\)\
\-\ often\\:\\ 0\\.028760536454006558\ \(0\)\
\-\ will\\:\\ 0\\.02836942913397531\ \(0\)\
\-\ such\\:\\ 0\\.028352865416761606\ \(0\)\
\-\ age\\:\\ 0\\.027672262456819002\ \(0\)\
\-\ brain\\:\\ 0\\.02747776888851266\ \(0\)\
\-\ t1\\:\\ 0\\.027463008671758247\ \(0\)\
\-\ fat\\:\\ 0\\.02741889644279224\ \(0\)\
\-\ decreased\\:\\ 0\\.02730248036319768\ \(0\)\
\-\ evaluation\\:\\ 0\\.026880904667485498\ \(0\)\
\-\ months\\:\\ 0\\.025656644716860265\ \(0\)\
\-\ one\\:\\ 0\\.025236411952916746\ \(0\)\
\-\ these\\:\\ 0\\.024890531727358625\ \(0\)\
\-\ consistent\\:\\ 0\\.0238998078087144\ \(0\)\
\-\ surgery\\:\\ 0\\.02369790396468676\ \(0\)\
\-\ noted\\:\\ 0\\.023369801971913382\ \(0\)\
\-\ can\\:\\ 0\\.0231304518716177\ \(0\)\
\-\ posterior\\:\\ 0\\.02279283203513341\ \(0\)\
\-\ it\\:\\ 0\\.022562633025602418\ \(0\)\
\-\ have\\:\\ 0\\.02201910636869995\ \(0\)\
\-\ after\\:\\ 0\\.02138269586078635\ \(0\)\
\-\ female\\:\\ 0\\.02126940490589191\ \(0\)\
\-\ treatment\\:\\ 0\\.02099643052521182\ \(0\)\
\-\ images\\:\\ 0\\.020388757351525986\ \(0\)\
\-\ that\\:\\ 0\\.019127962391270147\ \(0\)\
\-\ normal\\:\\ 0\\.017996529225758246\ \(0\)\
\-\ not\\:\\ 0\\.01740073064528189\ \(0\)\
\-\ an\\:\\ 0\\.01685507074276112\ \(0\)\
\-\ history\\:\\ 0\\.016840139392952935\ \(0\)\
\-\ this\\:\\ 0\\.015145807224383634\ \(0\)\
